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Fibrosis, the definition for which being the formation of fibrous tissue in an organ or a specific
region of the body, can often be a life threatening pathology or condition. Whilst fibrosis is often
readily discernable by simple histology, the causative triggers and events that lead to this excess
scarring often remain poorly understood by treating physicians, and the scientific community. Even
though there have been two recent notable Phase 3 clinical successes (King et al., 2014; Richeldi,
2014), resulting in the approval of pirfenidone and nintedanib for the treatment of idiopathic
pulmonary fibrosis (IPF), the availability of treatment options for patients is often modest and
often carry with them many side effects.
One of the key challenges faced in understanding fibrosis is that it is a pathological feature of
many diseases rather than a distinct disease by itself and therefore it spans multiple organs and
areas of the body. Consequently it is treated by many different specialty care physicians, such as
pulmonologists for IPF and nephrologists for renal fibrosis, therefore providing a broader scientific
base and diversity of opinions on how to treat diseases with significant fibrotic tissue.
To improve our understanding of these diseases, and in our attempts to bring new therapies
forward, it is also key that the patients perspective is given due consideration. In preparation
of this short commentary, we sought to get a view from individual patients following diagnosis
and living with their disease. As researchers, we focus on in vitro and in vivo models, and often
forget the end goal of what our pre-clinical systems are trying to address. Three individuals have
provided a personal view of when they were diagnosed with disease and how this impacts their
daily life. The diseases each person has been diagnosed with all have significant tissue fibrosis,
however they are very disparate conditions: idiopathic pulmonary fibrosis (IPF), systemic sclerosis
(SSc), and autoimmune liver cirrhosis. The extent and location of the fibrosis, and whether this
pathophysiology is contributing directly, or potentially being beneficial to the overall disease, is
different between each disease setting. However, whilst they are distinct diseases, these patients
appear to have similar experiences firstly the insidious onset of symptoms and slow progression
of their disease, which further delays a patient from presenting for medical attention, secondly
the unsuspecting clinical presentation of the disease, thirdly the complex management of the
symptoms, and finally the relentless impact on their quality of life. In the case of IPF, the extent
and progression of lung fibrosis is known to directly relate to disease progression and survival (Gay
et al, 1998). Fibrotic, aberrant collagen deposition directly impacts gas exchange and the increased
tissue stiffness alters the physiological capacity of the lung. In scleroderma, the impact of fibrosis is
more apparent in that there’s an obvious alteration in skin appearance and also any ensuing internal
organ fibrotic change manifesting in decreased function (Gabrielli et al., 2009). Fibrosis of the liver
can arise following a number of insults including toxins, viral infections and in the case of the
patient associated with this article, autoimmunity. It is known that tackling the cause of fibrosis
can allow for a spontaneous resolution of liver fibrosis, as observed with anti-viral in hepatitis c-
associated liver fibrosis, or alcohol cessation (Pellicoro et al., 2012). However, poor diet can also
play a significant impact on liver repair and fibrosis, and is emerging as a potential future major
cause of morbidity and mortality, particularly in those who are obese.
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The symptoms associated with organ fibrosis and loss of
function are often found in more common diseases. Therefore,
fibrotic disease is diagnosed following the exclusion of other
illnesses. This was the case for patient “MH” who was diagnosed
with IPF when he was 59. He first noticed a sudden shortness of
breath when he was at elevated altitude, which previously he had
ignored due to their infrequent nature in the earlier stages of the
disease. Many things can cause breathlessness, such as asthma,
allergies, respiratory infections, and therefore we all experience
this “common symptom of IPF.” However, it was only when he
was at altitude and the symptom persisted, that he soughtmedical
advice. He was initially diagnosed with cardiac insufficiency in
addition to his underlying asthma, therefore he was given a stent
and an inhaler. When his symptoms didn’t significantly improve
he was then referred to a pulmonologist, who diagnosed IPF. Due
to the rare nature of this condition it is perhaps not unsurprising
that it takes time to make a formal diagnosis of IPF, as one
presumes that the treating physicians are more likely to try and
exclude other common diseases where therapeutic options are
more readily available before presenting the diagnosis of IPF to
a patient. Likewise, patient “KF’s” condition of systemic sclerosis
also took 6 months before being diagnosed with her disease.
Whilst the priority of research should be on the discovery of new
therapeutic treatments, the thoughts raised from patients also
highlight the need for better tools and biomarkers to provide a
more rapid diagnosis of disease. Certainly, now that pirfenidone
and nintedanib have both been identified and approved for the
treatment of IPF, one presumes that treating patients in the early
stages of diseases would be preferential.
KF was ∼30 years old when she first noticed persistent
pins and needles, typically associated with Raynaud’s disease,
a condition affecting up to 20% of females. In KF’s case,
her physician sent her for follow up tests and was diagnosed
with systemic sclerosis (SSc). The challenge with diagnosing
conditions such as systemic sclerosis is that many diseases
can present in a similar way, such as mixed connective tissue
diseases with features of rheumatoid arthritis or systemic
lupus erythematosus, or even diseases like amyloidosis and
paraneoplastic syndromes. Recognizing the importance of
improvements in diagnosis, a new set of classification criteria
recently been proposed (van den Hoogen et al., 2013).
Nevertheless, these new criteria are complex and very subjective
with the only objective measure being the presence of SSc-
related autoantibodies. In the 6 months that it took to diagnose
KF, her ability to perform everyday tasks became significantly
worse such as brushing her hair or picking things off the floor.
This rapid deterioration is not uncommon and in recognition
of this the EUSTAR1 group has undertaken a study to define
preliminary criteria for the very early diagnosis of systemic
sclerosis (VEDOSS). Based on this study, early features are
the presence of anti-nuclear antibodies, SSc-specific antibodies,
SSc pattern on nailfold capillaroscopy and puffy fingers in
Raynaud syndrome patients (Minier et al., 2014). Unfortunately
even with early diagnosis there is currently no cure for SSc,
1http://www.gene.com/media/press-releases/14596/2015-06-10/fda-grants-break
through-therapy-designat.
however with increased monitoring the opportunity to manage
systems and to reduce the impact of some of the more severe
complications associated with this disease, such as pulmonary
arterial hypertension and renal crisis, should be improved. Hope
does remain that therapies are being developed that might tackle
this disease and it is noteworthy, and illustrates the eagerness
of regulatory authorities to bring medicines forward, that the
FDA recently gave Roches Actemra (tocilizumab), an anti-IL-
6 receptor antibody, breakthrough status for systemic sclerosis1
even though the primary endpoints weren’t met, but showed a
positive trend in Rodnin skin score, in their recent Phase II study
(Khanna et al., 2014).
Due to the diffuse nature of the fibrosis in SSc options for
transplanting affected organs are not possible. In the case of
IPF and autoimmune hepatitis, lung, or liver transplant remain
an option, but naturally this is often the last available option.
Patient ADL was only 17 when she was first diagnosed with
autoimmune hepatitis (AIH) after she observed a yellowing
of her eyes, a common diagnostic feature of liver injury and
damage. Like the previous described conditions the actual cause
of this fibrotic condition is unknown and due to the rare
nature of this condition diagnosis is more about excluding other
autoimmune conditions, such as thyroid disease or pernicious
anemia in as much as confirming the disease. Unlike IPF,
autoimmune diseases such as SSc and AIH, are both treated with
immunosuppressants, such as oral steroids and azathioprine,
with often limited success. Certainly, in ADL’s case this seemed
to be the case with her noting that “nothing seemed to help the
inflammation.” Tragically, the therapies provided often put the
patients at increased risk of infection. On her 20th birthday, ADL
was admitted to the intensive care unit with infected abdominal
ascites fluid from the scarred liver. Unfortunately, for AIH
patients the only therapeutic option for managing the disease
is maintaining patients on a life time of immunosuppressants
balancing inflammation versus the risk of infection, consequently
patients are regularly monitored and physicians are constantly
looking to taper down high dose steroids and manage their
patients with antibiotics. With little change in treatment course
or prognosis this can often leave many patients with a fibrotic
condition with a sense of loss, frustration, and depression about
their lives.
As can be seen in all of the patient perspectives, there is
significant morbidity associated with tissue fibrosis and also
a relatively poor prognosis, due to the lack of anti-fibrotic
therapies. Early diagnosis in many chronic diseases is known to
result in better outcomes. Detection of type 2 diabetes close to
disease onset can result in diet controlled glucose regulation and
the lack of need for medication; early cancer diagnosis can allow
for surgery and removal of tumors; early changes in intraocular
pressure can prevent glaucoma and preserve eyesight. Hopefully,
as our understanding of diseases associated with tissue fibrosis
increases, we may find more patients being diagnosed earlier in
their disease course, rather than diagnosing these conditions as a
matter of exclusion of other more common illnesses. Moreover,
the number of GWAS studies assessing risk factors for tissue
fibrosis may identify susceptibility markers that can identify
patients either early in their disease, or help prevent fibrosis from
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ever occurring (Radstake et al., 2010; Anstee and Day, 2013;
Fingerlin et al., 2013; Noth et al., 2013; Tampe and Zeisberg, 2014;
Zain et al., 2014).
Also, as we begin to dissect the causes of fibrosis, we will be
in a stronger position to prevent fibrosis thus retaining tissue
function. Liver fibrosis associated with hepatitis C infection is a
good example of this. Anti-virals have been reported to inhibit
hepatic fibrosis (Shiffman and Benhamou, 2015), but this is not
due to a direct effect of the compounds on portal fibroblasts or
collagen secretion, but actually due to the fibrosis being deposited
in the liver as a consequence of hepatitis C. Therefore, if you
remove the viral trigger, then the liver can repair itself. Another
example is the kidney, where high blood glucose is known to be
another fibrotic trigger as nephropathy is observed in diabetics
with poorly managed blood glucose. The triggers are less clear
in the lung, with many different factors being postulated such
as smoking or other environmental stimuli, radiation for cancer
therapies or certain medications (Oh et al., 2012). However, all of
these triggers have been observed in small groups of patients.
Currently, the medical and pharmaceutical community are
trying to find therapeutic options that can stop the progression
of disease and a number of these pathways are being tested
in clinical trials in different organs simultaneously, such
as anti-LOXL2, LPA1 inhibition or galectin-3 inhibition in
lung, liver, cardiac, and systemic fibrosis. Future approaches
may also be able to promote a resolution of fibrosis and
ultimately repair the damaged tissue. The liver regenerates after
hepatitis C eradication. The ability of the lung to regenerate is
controversial. However, in the acute setting of ARDS, patients
have diffuse alveolar damage, which exhibits many histologic
and radiographic features of IPF, and can go on to resolve the
fibrotic phenotypic changes (Lynch, 2001; Nöbauer-Huhmann
et al., 2001; Burnham et al., 2014), therefore indicating that lung
repair is possible.
What is striking about all fibrotic diseases is the loss of dignity
that many of these patients must feel, a sense of burden on
their family, an inability to take on common daily tasks such as
brushing your hair, and relying on help for basic bodily functions.
In addition all of these diseases leave the patients with disability
which makes them increasingly withdraw from society and the
broader family network. It is clear though that a close relationship
is often established with the treating physician and in many
cases the willingness of the patient to enroll and be involved in
experimental drug trials such as those being run by the IPFnet, or
to support patient support groups or charities for their respective
condition such as the Scleroderma Society or Pulmonary Fibrosis
Foundation. These support groups highlight a common feature
across fibrosis: the motivation of patients and physicians to help
advance our understanding of disease and ultimately be able to
provide therapeutic options to patients with these devastating
conditions.
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